Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.

Oncoimmunology · 2018 · PMC5993498 · PMID 29900046

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although PD patients had a higher median post-treatment VEGF-A than CR/PR/SD patients, it did not reach statistical significance (Supplementary Table S5; Supplementary Figure S7D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.